Publications

Risk of neutropenia-related hospitalisation among clozapine initiators

BMJ Ment Health.
Sarpatwari A, Mahesri M, Lii J, Lee SB, Zakoul H, Toyserkani GA, Zhou EH, Lacivita C, Dal Pan GJ, Bykov K, Moran L, Avorn J, Kesselheim AS, Huybrechts KF.

Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic

Drug Saf.
Hwang CS, Lu Z, Russo M, Zakoul H, Toyserkani GA, Zhou EH, LaCivita C, Dal Pan GJ, Kesselheim AS, Sarpatwari A.

Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies

Clin Pharmacol Ther.
Sarpatwari A, Lee SB, Zakoul H, Tekle W, Freedman A, Belitkar S, Toyserkani GA, LaCivita C, Zhou EH, Oswell KH, Dal Pan GJ, Kesselheim AS.

Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials

Drug Saf.
Chimonas S, Cosenza C, Kesselheim AS, Toyserkani GA, Oswell KH, LaCivita C, Dal Pan GJ, Sarpatwari A.

Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication

JAMA Health Forum.
Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD.

Impact Of Risk Evaluation And Mitigation Strategies On Generic Approvals Of US Pharmaceutical Products

Health Aff (Millwood).
Kao J, Van de Wiele VL, Beall RF, Sarpatwari A.

Isotretinoin Risk Evaluation and Mitigation Strategy and Pregnancy Incidence

JAMA Intern Med.
Zhu Y, Anand P, Sarpatwari A, Hernández-Díaz S, Bykov K, Kesselheim AS, Avorn J, Vine SM, Adomi M, DiCesare EC, Mahesri M, Zakoul H, Mogun H, Toyserkani GA, LaCivita C, Zhou EH, Dal Pan GJ, Huybrechts KF.

State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar.

JAMA Health Forum
Kwon Y, Sarpatwari A, Dusetzina SB.

Expansion of 340B Disproportionate Share Hospitals in the United States From 2010 to 2022.

Health Serv Res
Liu BY, Russo M, Kesselheim AS, Knox R, Sarpatwari A, Feldman WB.

Pediatric Exclusivity Revenues for Cancer Drugs.

JAMA Pediatr
Sarpatwari A, Bendicksen L, Hawkins DS, Gore L, Bourgeois FT.

Biosimilar approval pathways: comparing the roles of five medicines regulators.

J Law Biosci
Knox RP, Desai V, Sarpatwari A

Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.

Pediatr Blood Cancer
Liu ITT, Wang J, Sarpatwari A, Kesselheim AS, Feldman WB.

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020.

Drug Saf
Mahesri M, Sarpatwari A, Huybrechts KF, Lii J, Lee SB, Toyserkani GA, LaCivita C, Zhou EH, Dal Pan GJ, Kesselheim AS, Bykov K.

Biosimilar Uptake In The US: Patient And Prescriber Factors.

Health Aff (Millwood)
Hong D, Kesselheim AS, Sarpatwari A, Rome BN

Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.

JAMA Intern Med
Horrow C, Gabriele SME, Tu SS, Sarpatwari A, Kesselheim AS.

Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.

JAMA Netw Open
Feldman WB, Mahesri M, Sarpatwari A, Huybrechts KF, Zhu Y, Hwang CS, Lii J, Lee SB, Kattinakere Sreedhara S, Toyserkani GA, Zhou EH, Zendel L, LaCivita C, Manzo C, Dal Pan GJ, Kesselheim AS, Bykov K

Federal Trade Commission Actions on Prescription Drugs, 2000-2022.

JAMA
Daval CJR, Egilman AC, Sarpatwari A, Kesselheim AS.

Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.

Ann Intern Med
Egilman AC, Kesselheim AS, Sarpatwari A, Rome BN.

Use of Artificial Intelligence in Drug Development.

JAMA Netw Open
Druedahl LC, Price WN, Minssen T, Sarpatwari A.

Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.

JAMA
Sarpatwari A, Kohli S, Tu SS, Kesselheim AS.